Biohaven downgraded by BofA Securities with a new price target
$BHVN
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities downgraded Biohaven from Buy to Neutral and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/29/2026 | $11.00 | Neutral → Underperform | BofA Securities |
| 4/13/2026 | $21.00 | Buy | Canaccord Genuity |
| 2/6/2026 | $23.00 | Buy | Goldman |
| 1/21/2026 | $22.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 12/3/2025 | $11.00 | Buy → Neutral | H.C. Wainwright |
| 11/26/2025 | $11.00 | Buy → Neutral | UBS |
| 11/6/2025 | $9.00 | Outperform → Mkt Perform | Bernstein |
| 11/5/2025 | $10.00 | Buy → Neutral | BofA Securities |
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types. Differentiated safety profile: No dose-limiting toxicities and no FGFR inhibitor-class toxicities observed, supporting a potentially broader therapeutic index than approved FGFR tyrosine kinase inhibitors (TKIs).Potential to expand the addressable FGFR3 population
David Pirman, Ph.D. promoted to Executive Vice President and Head of DiscoveryBruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborationsWarren Volles, General Counsel and Chief Legal Officer, also designated an executive officerNEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this role, Dr. Pirman will lead the Company's internal drug-discovery organ
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profileIn the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs High double-blind completion rates of ~95%, and high
8-K - Biohaven Ltd. (0001935979) (Filer)
SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)
8-K - Biohaven Ltd. (0001935979) (Filer)
3 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
BofA Securities downgraded Biohaven from Neutral to Underperform and set a new price target of $11.00
Canaccord Genuity initiated coverage of Biohaven with a rating of Buy and set a new price target of $21.00
Goldman initiated coverage of Biohaven with a rating of Buy and set a new price target of $23.00
4/A - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)
Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
SC 13G/A - Biohaven Ltd. (0001935979) (Subject)
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi